骨髓增殖性肿瘤分子靶向治疗策略  

The progress of molecular targeted therapy of myeloproliferative neoplasm

作　　者：任媛媛[1] 张凌岩[1] 李英[1] 

机构地区：[1]山东大学附属省立医院血液科,250021

出　　处：《新医学》2012年第5期281-284,共4页Journal of New Medicine

基　　金：山东省自然科学基金(Y2007C059)

摘　　要：骨髓增殖性肿瘤以一系或多系髓系细胞增殖为特点,近年来发现的活化酪氨酸激酶突变JAK2V617F在某些类型骨髓增殖性肿瘤的分子发病机制中可能发挥关键作用,该发现极大地推动了选择性JAK2抑制剂用于治疗骨髓增值性肿瘤的研究发展。该文总结了JAK2抑制剂在骨髓增殖性肿瘤靶向治疗中的地位,并分析了其可能带来的益处和面临的挑战。Myeloproliferative neoplasms （MPN） are characterized by the abnormal proliferation of one or more myeloid cell lines. The activating tyrosine kinase mutation JAK2V617F may play a key role in the molecular patho- genesis of certain types of MPN. The discovery has greatly promoted the development of JAK2-selective inhibitors for the treatment of MPN. This review summarizes the status of JAK2 inhibitors in targeted therapy of MPN and discusses their benefits and challenges.

关 键 词：骨髓增殖性肿瘤 JAK2V617F 靶向治疗 

分 类 号：R551.3[医药卫生—血液循环系统疾病]